1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

2. Nowell PC. Progress with chronic myelogenous leukemia: a personal perspective over four decades. Annu Rev Med. 2002;53:1-13.

3. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukemia. Acta Haematol. 2002;108:180-202.

4. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;93:3167-3215.

5. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337-1354.

6. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996;88:2410-2414.

7. Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19:313-317.

8. Shepter PJ, Ben-Yehuda D. Molecular evolution of chronic myeloid leukaemia. Semin Cancer Biol. 2001;11:313-322.

9. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022.

10. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76-94.

11. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102:1160-1168.

12. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukemia. Acta Haema-tol. 2002;107:64-75.

13. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med. 2002;53:369-381.

14. Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with ima-tinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-166.

15. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med. 2003;348:994-1004.

16. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003;17:2401-2409.

17. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Eng J Med. 2003;349:1423-1432.

18. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.

19. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-a-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041.

20. Deininger M, Buchdunger E, Druker BJ. The development of ima-tinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.

21. Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma. 2003;44:23-28.

22. Tsao AS, Kantarjian H, Talpaz DM. STI-571 in chronic myelogenous leukemia. Br J Haematol. 2002;119:15-24.

23. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell. 2002;2:99-102.

24. Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004;104:2926-2932.

25. Wang YL, Bagg A, Pear W, et al. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. Genes Chromosomes Cancer. 2001;32:97-111.

26. Bagg A. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J Mol Diag. 2002;4:1-10.

27. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999;107:587-599.

28. Hochhaus A. Detection and quantification of leukemia-specific rearrangements. In: Boultwood J, Fidler C, eds. Methods in Molecular Medicine. Totowa, NJ: Humana Press; 2002:67-96.

29. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. Br J Haematol. 2002;117:875-877.

30. Lichty BD, Keating A, Callum J, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol. 1998;103:711-715.

31. Kreuzer KA, Lass U, Bohn A, et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res. 1999;59: 3171-3174.

32. Emig M, Saussele S, Wittor H, et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia. 1999;13:1825-1832.

33. Serrano J, Roman J, Sanchez J, et al. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 (BCR-ABL) and p190 (BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 (BCR-ABL) detection precede cytoge-netic relapse. Blood. 2000;95:2659-2665.

34. Formankova R, Honzatkova L, Moravcova J, et al. Prediction and reversion of post-transplant relapse in patients with chronic myeloid leukemia using mixed chimerism and residual disease detection and adoptive immunotherapy. Leuk Res. 2000;24:339-347.

35. Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in cells of some healthy individuals. Blood. 1995;86:3118-3122.

36. Bose S, Deininger M, Gora-Tybor J, et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998;92:3362-3367.

37. Radich JP, Gehley G, Gooley T, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632-2638.

38. Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood. 2001;98:1701-1707.

39. Chomel JC, Brizard F, Veinstein A, et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood. 2000;95:404-408.

40. Lion T. Clinical implications of qualitative and quantitative poly-merase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia: The European Investigators on Chronic Myelogenous Leukemia Group. Bone Marrow Transplant. 1994;14:505-509.

41. Wang L, Pearson K, Ferguson JE, et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003;120:990-999.

42. Marin D, Kaeda J, Szydlo R, et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia. 2005;19:507-512.

43. Tipping AJ, Deininger MW, Goldman JM, et al. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp Hematol. 2003;31:1073-1080.

44. Vergilio J, Bagg A. Chronic myeloid leukemia: Molecular diagnosis and monitoring. In: Fuchs J, Podda M, eds. Encyclopedia of Medical Genomics and Proteomics. New York: Marcel Dekker; 2005.

45. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005;12:33-39.

46. O'Dwyer ME, Gatter KM, Loriaux M, et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003;17:481-487.

47. Saussele S, Weisser A, Muller MC, et al. Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes. Leukemia. 2000;14:2006-2010.

48. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51-57.

49. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med. 2005;352:1744-1746.

50. Tefferi A, Gilliland DG. The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc. 2005;80:947-958.

51. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272-4290.

52. Harrison CN. Current trends in essential thrombocythemia. Br J Haematol. 2002;117:796-808.

53. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002;108:55-65.

54. Vergilio J, Bagg A. Myelodysplastic syndromes: contemporary biologic concepts and emerging diagnostic approaches. Am J Clin Pathol. 2003;199(suppl):S58-S77.

55. Greiner TC. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders. Am J Clin Pathol. 2006;125: 651-653.

56. Cherian S, Bagg A. The genetics of the myelodysplastic syndromes: Classical cytogenetics and recent molecular insights. Hematology. 2006;11:1-13.

57. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. 2002;107:101-107.

58. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol. 2002;107:113-122.

59. Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300.

60. Gupta R, Bain BJ, Knight CL. Cytogenetic and molecular genetic abnormalities in systemic mastocytosis. Acta Haematol. 2002;107: 123-128.

61. Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol. 2000;111:873-874.

62. Emanuel PD. Juvenile myelomonocytic leukemia. Curr Hematol Rep. 2004;3:203-209.

63. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Eng J Med. 1997;336: 1713-1720.

64. Kita-Sasai Y, Horiike S, Misawa S, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndromes. Br J Haema-tol. 2001;115:309-312.

65. Lai JL, Preudhomme C, Roumier C, et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia. 1995;9:370-381.

66. Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndromes. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008-1015.

67. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985-2990.

68. Tien H-F, Tang J-L, Tsay W, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148-154.

69. Padua RA, Guinn BA, Al-Sabah AI, et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 1998;12:887-892.

70. Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: a report from an international workshop. Genes Chromosomes Cancer. 2002; 33:379-394.

71. Reddy PL, Sheet VT, Dutt D, et al. Increased incidence of mito-chondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol. 2002;116:564-575.

72. Gattermann N. From sideroblastic anemia to the role of mitochon-drial DNA mutations in myelodysplastic syndromes. Leuk Res. 2000;24:141-151.

73. Gale RE. Evaluation of clonality in myeloid stem-cell disorders. Semin Hematol. 1999;36:361-372.

74. Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of Hpall and HhaI sites near the polymorphic CAG repeat in the human andro-gen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229-1239.

75. Uchida T, Ohashi H, Aoki E, et al. Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP). Leukemia. 2000;14:207-212.

76. Briere J, el-Kassar N. Clonality markers in polycythaemia and primary thrombocythaemia. Baillieres Clin Haematol. 1998;11: 787-801.

77. Klippel S, Strunck E, Busse CE, et al. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood. 2002;100:2441-2448.

78. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.

Section V

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment